var data={"title":"Captopril: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Captopril: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5807?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=captopril-patient-drug-information\" class=\"drug drug_patient\">see &quot;Captopril: Patient drug information&quot;</a> and <a href=\"topic.htm?path=captopril-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Captopril: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708658\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Fetal toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">When pregnancy is detected, discontinue captopril as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145364\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Capto;</li>\n      <li>Dom-Captopril;</li>\n      <li>Mylan-Captopril;</li>\n      <li>PMS-Captopril;</li>\n      <li>Teva-Captopril</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145413\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Angiotensin-Converting Enzyme (ACE) Inhibitor;</li>\n      <li>\n        Antihypertensive</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145368\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Titrate dose according to patient's response; use lowest effective dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic nephropathy:</b> Oral: Initial: 25 mg 3 times daily. May be taken with other antihypertensive therapy if required to further lower blood pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heart failure with reduced ejection fraction (HFrEF) (ACCF/AHA [Yancy 2013]):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial dose: 6.25 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Target dose: 50 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b> Oral: Initial dose: 25 mg 2 to 3 times daily (a lower initial dose of 12.5 mg 3 times daily may also be considered [VA Cooperative Study Group 1984]); may increase at 1- to 2-week intervals up to 50 mg 3 times daily; add thiazide diuretic, unless severe renal impairment coexists then consider loop diuretic, before further dosage increases or consider other treatment options; maximum dose: 450 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Target dose (JNC 8 [James 2013]): 75 to 100 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Usual dose range (7ASH/ISH [Weber 2014]): 50 to 100 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>LV dysfunction following MI:</b> Oral: Initial: 6.25 mg; if tolerated, follow with 12.5 mg 3 times daily; then increase to 25 mg 3 times daily during next several days and then gradually increase over next several weeks to target dose of 50 mg 3 times daily (some dose schedules are more aggressive to achieve an increased goal dose within the first few days of initiation). <b>Note:</b> In those patients with STEMI in the anterior location, heart failure, or LV ejection fraction &le;0.4, an ACE inhibitor (eg, captopril) should be initiated within the first 24 hours after MI (ACCF/AHA [O'Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute hypertension (urgency/emergency) </b>\n      <b>(off-label use):</b> Oral, sublingual: 25 mg, may repeat as needed; consider alternative therapy if blood pressure is nonresponsive within 20 to 30 minutes (Angeli 1991, Castro del Castillo 1988, Ceyhan 1990, Damasceno 1997, Tschollar 1985). <b>Note:</b> May be given sublingually, but therapeutic advantage has not been demonstrated over oral administration (Karakilic 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Raynaud phenomenon (off-label use):</b> Oral: 12.5 mg twice daily; may gradually increase to 25 mg 3 times daily (Tosi 1987). Clinical trial evaluated patients for up to 3 months. Additional data is necessary to further define the role of captopril in the treatment of this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145389\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=captopril-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Captopril: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Titrate dose according to patient's response; use lowest effective dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension (off label use):</b> Children &le;1 year and Adolescents &le;17 years: Oral: Initial: 0.3 to 0.5 mg/kg/dose every 8 hours; may titrate upward to maximum of 6 mg/kg/<b>day</b> in 3 divided doses (NHBPEP 2004, NHLBI 2011); maximum daily dose: 450 mg/day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145369\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. In the management of hypertension, consider lower initial doses and titrate to response (Aronow 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145370\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Manufacturers recommendations:</i> Reduce initial daily dose and titrate slowly (1- to 2-week intervals) with smaller increments. Slowly back titrate to determine the minimum effective dose once the desired therapeutic effect has been reached.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Alternative recommendations (Aronoff 2007):</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 50 mL/minute: Administer at 75% of normal dose every 12 to 18 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute: Administer at 50% of normal dose every 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent hemodialysis (IHD): Administer after hemodialysis on dialysis days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis: Dose for CrCl 10 to 50 mL/minute; supplemental dose is not necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents: <b>Note:</b> Renally adjusted dose recommendations are based on doses of 0.1 to 0.5 mg/kg/dose every 6 to 8 hours; maximum daily dose: 6 mg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent hemodialysis: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis (PD): Administer 50% of dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15682459\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145337\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 12.5 mg, 25 mg, 50 mg, 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145321\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23610421\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral: 6.25 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802614\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer at least 1 hour before meals. Unstable in aqueous solutions; to prepare solution for oral administration, mix prior to administration and use within 10 minutes (Allen 1996).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145340\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic nephropathy:</b> Treatment of diabetic nephropathy (proteinuria &gt;500 mg/day) in patients with type 1 insulin-dependent diabetes mellitus and retinopathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heart failure:</b> Treatment of heart failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b> Management of hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Left ventricular dysfunction after myocardial infarction:</b> To improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction of 40% or less, and to reduce the incidence of overt heart failure and subsequent hospitalizations for heart failure in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Guideline recommendations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heart failure:</b> The American College of Cardiology Foundation/American Heart Association (ACCF/AHA) 2013 heart failure guidelines recommend the use of angiotensin-converting enzyme (ACE) inhibitors, along with other guideline directed medical therapies, to prevent heart failure in patients with a reduced ejection fraction who have a history of myocardial infarction (stage B heart failure), to prevent heart failure in any patient with a reduced ejection fraction (stage B heart failure), or to treat those with heart failure and reduced ejection fraction (stage C heart failure) (Yancy 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension:</b> The 2014 guideline for the management of high blood pressure in adults (Eighth Joint National Committee [JNC 8]) recommends initiation of pharmacologic treatment to lower blood pressure for the following patients:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Patients &ge;60 years with systolic blood pressure (SBP) &ge;150 mm Hg or diastolic blood pressure (DBP) &ge;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Patients &lt;60 years with SBP &ge;140 mm Hg or DBP is &ge;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Patients &ge;18 years with diabetes and SBP &ge;140 mm Hg or DBP &ge;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Patients &ge;18 years with chronic kidney disease (CKD) and SBP &ge;140 mm Hg or DBP &ge;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Coronary artery disease (CAD) and hypertension:</b> The American Heart Association, American College of Cardiology and American Society of Hypertension (AHA/ACC/ASH) 2015 scientific statement for the treatment of hypertension in patients with CAD recommends the use of an ACE inhibitor (or an ARB) as part of a regimen in patients with hypertension and chronic stable angina if there is prior MI, LV systolic dysfunction, diabetes mellitus, or CKD. A BP target of &lt;140/90 mm Hg is reasonable for the secondary prevention of cardiovascular events. A lower target BP (&lt;130/80 mm Hg) may be appropriate in some individuals with CAD, previous MI, stroke or transient ischemic attack, or CAD risk equivalents (AHA/ACC/ASH [Rosendorff 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Diabetes and hypertension:</b> The American Diabetes Association (ADA) guidelines recommend an ACE inhibitor (or an ARB) for patients with HTN and diabetes with albuminuria (urinary albumin-to-creatinine ratio [UACR] &ge;30 mg/g). For patients with hypertension and diabetes <i>without</i> albuminuria, any of the 4 classes of blood pressure medications (eg, ACE inhibitors, ARBs, thiazide-like diuretics, dihydropyridine calcium channel blockers) may be used and have shown beneficial cardiovascular outcomes (ADA 2017a).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>STEMI:</b> The 2013 American College of Cardiology Foundation/American Heart Association guidelines for the management of patients with ST-elevation myocardial infarction (STEMI) states that an ACE inhibitor (eg, captopril) should be initiated within the first 24 hours after STEMI in patients with anterior MI, heart failure, or left ventricular ejection fraction &le;40%. It is also reasonable to initiate an ACE inhibitor in all patients with STEMI (ACCF/AHA [O'Gara 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25722081\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Aldosteronism (diagnosis); Hypertension secondary to scleroderma renal crisis; Hypertensive crisis; Improve kidney outcomes in hypertensive patients with chronic kidney disease (CKD) (diabetic and nondiabetic population); Pediatric hypertension; Postmyocardial infarction for prevention of heart failure; Raynaud phenomenon; Non&ndash;ST-elevation acute coronary syndrome; Anatomic renal artery stenosis (diagnosis); Bartter's syndrome; Hypertension secondary to Takayasu's disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145421\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Captopril may be confused with calcitriol, Capitrol, carvedilol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Acepril [Great Britain] may be confused with Accupril which is a brand name for quinapril in the US</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Acepril: Brand name for captopril [Great Britain], but also the brand name for enalapril [Hungary, Switzerland]; lisinopril [Malaysia]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145328\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Frequency not defined: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Angina pectoris, cardiac arrest, cardiac arrhythmia, cardiac failure, flushing, myocardial infarction, orthostatic hypotension, Raynaud's phenomenon, syncope </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Ataxia, cerebrovascular insufficiency, confusion, depression, drowsiness, myasthenia, nervousness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Bullous pemphigoid, erythema multiforme, exfoliative dermatitis, pallor, Stevens-Johnson syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Gynecomastia, hyponatremia (symptomatic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Cholestasis, dyspepsia, glossitis, pancreatitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Impotence, nephrotic syndrome, oliguria, urinary frequency</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Agranulocytosis, anemia, pancytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Hepatic necrosis (rare), hepatitis, increased serum alkaline phosphatase, increased serum bilirubin, increased serum transaminases, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Anaphylactoid reaction, angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Blurred vision </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Polyuria, renal failure, renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Bronchospasm, eosinophilic pneumonitis, rhinitis </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypotension (1% to 3%), chest pain (1%), palpitations (1%), tachycardia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (maculopapular or urticarial [4% to 7%]; in patients with rash, a positive ANA and/or eosinophilia has been noted in 7% to 10%), pruritus (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hyperkalemia (1% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Dysgeusia (2% to 4%; loss of taste or diminished perception)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Proteinuria (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Neutropenia (&le;4%; in patients with renal insufficiency or collagen-vascular disease)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction (rash, pruritus, fever, arthralgia, and eosinophilia: 4% to 7%; depending on dose and renal function)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Increased serum creatinine, renal insufficiency (worsening; may occur in patients with bilateral renal artery stenosis or hypovolemia) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cough (&lt;1% to 2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Hypersensitivity reactions (rash, pruritus, fever, arthralgia, and eosinophilia) have occurred in 4% to 7% of patients (depending on dose and renal function); dysgeusia - loss of taste or diminished perception (2% to 4%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, alopecia, angina pectoris, anorexia, aphthous stomatitis, aplastic anemia, arthralgia, cholestatic jaundice, constipation, diarrhea, dizziness, dyspnea, eosinophilia, fatigue, fever, gastric irritation, glomerulonephritis, Guillain-Barre syndrome, headache, hemolytic anemia, Huntington's chorea (exacerbation), hyperthermia, increased erythrocyte sedimentation rate, insomnia, interstitial nephritis, Kaposi's sarcoma, malaise, myalgia, nausea, paresthesia, peptic ulcer, pericarditis, psoriasis, seizure (in premature infants), systemic lupus erythematosus, vasculitis, visual hallucination (Doane, 2013), vomiting, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145344\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to captopril, any other ACE inhibitor, or any component of the formulation; angioedema related to previous treatment with an ACE inhibitor; concomitant use with aliskiren in patients with diabetes mellitus; coadministration with or within 36 hours of switching to or from a neprilysin inhibitor (eg, sacubitril).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Concomitant use with aliskiren in patients with moderate to severe renal impairment (GFR &lt;60 mL/minute/1.73 m<sup>2</sup>).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145325\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Angioedema: At any time during treatment (especially following first dose) angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans and patients with idiopathic or hereditary angioedema may be at an increased risk. Risk may also be increased with concomitant use of mTOR inhibitor (eg, everolimus) therapy or a neprilysin inhibitor (eg, sacubitril). Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with previous angioedema associated with ACE inhibitor therapy is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis (some fatal); discontinue if marked elevation of hepatic transaminases or jaundice occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1 to 4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Captopril has been associated with neutropenia with myeloid hypoplasia and agranulocytosis; anemia and thrombocytopenia have also occurred. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Closely monitor CBC with differential for the first 3 months of therapy and periodically thereafter in these patients. Onset of neutropenia is usually within 3 months of captopril initiation. Neutrophil count generally returns to baseline within 2 weeks of discontinuation. If neutropenia develops (neutrophil count &lt;1,000/mm<sup>3</sup>), discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: May occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proteinuria: Total urinary proteins greater than 1 g per day have been reported (&lt;1%); nephrotic syndrome occurred in about one-fifth of proteinuric patients. In most cases, proteinuria subsided or cleared within six months (whether or not captopril was continued).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in BUN and serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small benign increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function (Bakris 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aortic stenosis: Use with caution in patients with aortic stenosis; may reduce coronary perfusion resulting in ischemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition (ACCF/AHA [Gersh 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal artery stenosis: Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in preexisting renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Black patients: ACE inhibitors effectiveness is less in black patients than in non-blacks. In addition, ACE inhibitors cause a higher rate of angioedema in black than in non-black patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery: In patients on chronic ACE inhibitor therapy, intraoperative hypotension may occur with induction and maintenance of general anesthesia; use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss, or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension. However, discontinuation of therapy prior to surgery is controversial. If continued preoperatively, avoidance of hypotensive agents during surgery is prudent (Hillis 2011). Based on current research and clinical guidelines in patients undergoing non-cardiac surgery, continuing ACE inhibitors is reasonable in the perioperative period. If ACE inhibitors are held before surgery, it is reasonable to restart postoperatively as soon as clinically feasible (ACC/AHA [Fleisher 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extemporaneous oral solutions: Extemporaneous preparations of liquid formulations may vary; this may affect the rate and extent of absorption causing intrapatient variability regarding dosing and safety profile for the patient; use with caution and monitor closely if dosage formulations are changed (Bhatt 2011, Mulla 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145407\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145330\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9196&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Aliskiren may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Aliskiren may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Management: Aliskiren use with ACEIs or ARBs in patients with diabetes is contraindicated. Combined use in other patients should be avoided, particularly when CrCl is less than 60 mL/min. If combined, monitor potassium, creatinine, and blood pressure closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: Angiotensin-Converting Enzyme Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II: Angiotensin-Converting Enzyme Inhibitors may enhance the therapeutic effect of Angiotensin II. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Angiotensin II Receptor Blockers may increase the serum concentration of Angiotensin-Converting Enzyme Inhibitors. Management: In US labeling, use of telmisartan and ramipril is not recommended. It is not clear if any other combination of an ACE inhibitor and an ARB would be any safer. Consider alternatives to the combination when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Captopril.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprotinin: May diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: Angiotensin-Converting Enzyme Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canagliflozin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Canagliflozin may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): Angiotensin-Converting Enzyme Inhibitors may enhance the arrhythmogenic effect of Ciprofloxacin (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipeptidyl Peptidase-IV Inhibitors: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Drospirenone: Angiotensin-Converting Enzyme Inhibitors may enhance the hyperkalemic effect of Drospirenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ferric Gluconate: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ferric Hydroxide Polymaltose Complex: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Ferric Hydroxide Polymaltose Complex. Specifically, the risk for angioedema or allergic reactions may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gelatin (Succinylated): Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Gelatin (Succinylated). Specifically, the risk of a paradoxical hypotensive reaction may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gold Sodium Thiomalate: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grass Pollen Allergen Extract (5 Grass Extract): Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). Specifically, ACE inhibitors may increase the risk of severe allergic reaction to Grass Pollen Allergen Extract (5 Grass Extract). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Icatibant: May diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Dextran Complex: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Angiotensin-Converting Enzyme Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Angiotensin-Converting Enzyme Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Salts: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pregabalin: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Pregabalin. Specifically, the risk of angioedema may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sacubitril: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Sacubitril. Specifically, the risk of angioedema may be increased with this combination. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Salicylates may diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: Angiotensin-Converting Enzyme Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Thiazide and Thiazide-Like Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: May enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145358\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Captopril serum concentrations may be decreased if taken with food. Long-term use of captopril may lead to a zinc deficiency which can result in altered taste perception. Management: Take on an empty stomach 1 hour before or 2 hours after meals. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145333\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145347\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">\n      <b>[US Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.</b> Captopril crosses the placenta (Hurault de Lingy 1987). Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Their use in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Teratogenic effects may occur following maternal use of an ACE inhibitor during the first trimester, although this finding may be confounded by maternal disease. Because adverse fetal events are well documented with exposure later in pregnancy, ACE inhibitor use in pregnant women is not recommended (Seely 2014; Weber 2014). Infants exposed to an ACE inhibitor in utero should be monitored for hyperkalemia, hypotension, and oliguria. Oligohydramnios may not appear until after irreversible fetal injury has occurred. Exchange transfusions or dialysis may be required to reverse hypotension or improve renal function, although data related to the effectiveness in neonates is limited.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant and mother. ACE inhibitors are not recommended for the treatment of uncomplicated hypertension in pregnancy (ACOG 2013) and they are specifically contraindicated for the treatment of hypertension and chronic heart failure during pregnancy by some guidelines (Regitz-Zagrosek 2011). In addition, ACE inhibitors should generally be avoided in women of reproductive age (ACOG 2013). If treatment for hypertension or chronic heart failure in pregnancy is needed, other agents should be used (ACOG 2013; Regitz-Zagrosek 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6195942\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Captopril is present in breast milk. Concentrations of captopril in breast milk are ~1% of those in maternal blood. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Some guidelines consider captopril to be acceptable for use in breastfeeding women. Monitoring of the breastfeeding child's weight for the first 4 weeks is recommended (Regitz-Zagrosek 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145335\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">BUN, electrolytes, serum creatinine; blood pressure. In patients with renal impairment and/or collagen vascular disease, closely monitor CBC with differential for the first 3 months of therapy and periodically thereafter.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <i>2013 ACCF/AHA Heart Failure guideline recommendations:</i> Within 1 to 2 weeks after initiation and periodically thereafter, reassess renal function and serum potassium especially in patients with preexisting hypotension, hyponatremia, diabetes mellitus, azotemia, or those taking potassium supplements (ACCF/AHA [Yancy 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50148483\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension: </b>The 2014 guideline for the management of high blood pressure in adults (Eighth Joint National Committee [JNC 8]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;60 years: Goal of therapy is SBP &lt;150 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &lt;60 years: Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;18 years with diabetes: Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;18 years with chronic kidney disease (CKD): Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes and hypertension: </b>The American Diabetes Association (ADA) guidelines (ADA 2017a; ADA 2017b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;18 to &le;65 years: Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients &ge;18 to &le;65 years <b>and</b> at high risk of cardiovascular disease: Goal of therapy is SBP &lt;130 mm Hg and DBP &lt;80 mm Hg (if can be achieved without undue treatment burden).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patents &ge;65 years (healthy <b>or </b>complex/intermediate health): Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patents &ge;65 years (very complex/poor health): Goal of therapy is SBP &lt;150 mm Hg and DBP &lt;90 mm Hg.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145324\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145343\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Within 15 minutes; Peak effect: Blood pressure reduction: 1 to 1.5 hours after dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maximum effect: Antihypertensive: 60 to 90 minutes; may require several weeks of therapy before full hypotensive effect is seen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Dose related, may require several weeks of therapy before full hypotensive effect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: 60% to 75%; rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 0.7 L/kg (Duchun 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: ~60% to 75% (Kubo 1985); reduced 30% to 40% by food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 25% to 30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: 50% metabolized</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants with CHF: 3.3 hours; range: 1.2 to 12.4 hours (Pereira 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: 1.5 hours; range: 0.98 to 2.3 hours (Levy 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults, healthy volunteers: ~1.7 hours (Duchin 1982). In 2 studies, patients with chronic renal failure demonstrated ~2-fold longer half-lives as compared to normal subjects (Giudicelli 1984; Onoyama 1981). Half-life was up to 21 hours in patients with severe renal impairment and up to 32 hours in patients on chronic hemodialysis in another study (Duchin 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Within 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&gt;95%) within 24 hours (40% to 50% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145346\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Captopril Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (100): $155.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $166.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $289.87</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $380.63</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145350\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ace-Bloc (TW);</li>\n      <li>Aceomel (IE);</li>\n      <li>Acepress (ID, IT);</li>\n      <li>Acepril (GB, LK);</li>\n      <li>Aceril (IL);</li>\n      <li>Acetab (AE, ET, QA);</li>\n      <li>Aceten (IN);</li>\n      <li>Adocor (DE);</li>\n      <li>Amipril (BD);</li>\n      <li>Angiopril (IN);</li>\n      <li>Angiopril-25 (ZW);</li>\n      <li>Antasten (AR);</li>\n      <li>Apuzin (LK, MY);</li>\n      <li>Asisten (UY);</li>\n      <li>Atrisol (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Bloc-Med (PH);</li>\n      <li>Brucap (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Caipolex (ZW);</li>\n      <li>Capace (ZA);</li>\n      <li>Capocard (JO, KW, QA, SA);</li>\n      <li>Capomed (PH);</li>\n      <li>Caporex (ZW);</li>\n      <li>Capotec (PH);</li>\n      <li>Capoten (AE, AU, BB, BE, BH, BM, BR, BS, BZ, CL, CN, CO, CY, CZ, DK, EC, EG, ES, ET, FI, GB, GR, GY, HK, IE, IT, JM, JO, KE, KW, LB, LK, LU, NG, NL, NZ, PH, PK, PL, PT, QA, SA, SE, SR, TR, TT, TZ, UG, VE, ZA, ZM);</li>\n      <li>Capotena (MX);</li>\n      <li>Capotril (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Capril (BD, KR, SA, TH);</li>\n      <li>Captace (AE, PH);</li>\n      <li>Captarsan (VN);</li>\n      <li>Captensin (ID);</li>\n      <li>Captodoc (DE);</li>\n      <li>Captoflux (DE);</li>\n      <li>Captohexal (EE, LU, NZ);</li>\n      <li>Captolane (FR);</li>\n      <li>Captolar (LK);</li>\n      <li>Captomed (QA);</li>\n      <li>Captopren (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Captopril Pharmavit (HU);</li>\n      <li>Captor (AT, IE);</li>\n      <li>Captotec (BR);</li>\n      <li>Captral (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Cardiagen (DE);</li>\n      <li>Catopil (BD);</li>\n      <li>Catoplin (SG);</li>\n      <li>Debax (AT);</li>\n      <li>Dexacap (ID, SG, VN);</li>\n      <li>Ecaten (MX);</li>\n      <li>Epsitron (ET);</li>\n      <li>Farcopril (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Farmoten (ID);</li>\n      <li>Gemzil (TH);</li>\n      <li>Hartylox (PH);</li>\n      <li>Hiperil (PT);</li>\n      <li>Huma-Captopril (HU);</li>\n      <li>Hypopress (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Hypotensor (GR);</li>\n      <li>Kapril (TR);</li>\n      <li>Kaptopril (LV);</li>\n      <li>Ketanine (SG);</li>\n      <li>Kimapan (MY);</li>\n      <li>Lopirin (AT, CH, DE);</li>\n      <li>Lopril (FI, FR);</li>\n      <li>Metopril (ID);</li>\n      <li>Midopril (KW);</li>\n      <li>Midrat (MX);</li>\n      <li>Minitent (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Nolectin (PE);</li>\n      <li>Normolose (MT);</li>\n      <li>Noyada (GB, MT);</li>\n      <li>Pertacilon (SG);</li>\n      <li>Prelat (PH);</li>\n      <li>Primace (PH);</li>\n      <li>Properil (CL);</li>\n      <li>Retensin (PH);</li>\n      <li>Rilcapton (SG);</li>\n      <li>Ropril (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, MT, OM, SA, SY, TR, YE);</li>\n      <li>Smarten (TW);</li>\n      <li>Tensicap (ID);</li>\n      <li>Tensiomen (BG, SK, VN);</li>\n      <li>Tensiomin (HU);</li>\n      <li>Tensobon (DE);</li>\n      <li>Topril (BD);</li>\n      <li>Vasosta (PH);</li>\n      <li>Zapto (ZA);</li>\n      <li>Zedace (AU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Allen LV Jr and Erickson MA 3rd, Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids. <i>Am J Health-Syst Pharm</i>. 1996; 53(18):2179-2184.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/8879325/pubmed\" target=\"_blank\" id=\"8879325\">8879325</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, &ldquo;Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),&rdquo; <i>JAMA</i>, 2002, 288(23):2981-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/12479763/pubmed\" target=\"_blank\" id=\"12479763\">12479763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists&rsquo; Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/24150027 /pubmed\" target=\"_blank\" id=\"24150027 \">24150027 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27979896\"></a>American Diabetes Association. Cardiovascular disease and risk management. <i>Diabetes Care. </i>2017a;40(suppl 1):S75-S87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/27979896/pubmed\" target=\"_blank\" id=\"27979896\">27979896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27979898\"></a>American Diabetes Association. Older adults. <i>Diabetes Care</i>. 2017b;40(suppl 1):S99&ndash;S104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/27979898/pubmed\" target=\"_blank\" id=\"27979898\">27979898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amsterdam EA, Wenger NK, Brindis RG, et al; ACC/AHA Task Force Members; Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(25):2354-2394.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2012448\"></a>Angeli P, Chiesa M, Caregaro L, et al. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomized, single-blind clinical trial. <i>Arch Intern Med</i>. 1991;151(4):678-682.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/2012448/pubmed\" target=\"_blank\" id=\"2012448\">2012448</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo; <i>Circulation</i>, 2004, 110(5):588-636.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/15289388/pubmed\" target=\"_blank\" id=\"15289388\">15289388</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Apo-Capto (captopril) [product monograph]. Weston, Ontario, Canada: Apotex Inc; November 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p. 28.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo; <i>Circulation</i>, 2011, 123(21):2434-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/21518977/pubmed\" target=\"_blank\" id=\"21518977\">21518977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bakris GL, Maron BJ, Bonow RO, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice, American Association for tharacic Surgey; American Society of Echocardiography, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>J Thorac Cardiovasc Surg</i>. 2011;142(6):e153-e203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/22093723/pubmed\" target=\"_blank\" id=\"22093723\">22093723</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt MD, Thomas JE, and Mondal TK. Variation in Captopril Formulations in Pharmacies Across Canada. <i>Paediatr Child Health</i>. 2011;16(4):e30-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/22468132/pubmed\" target=\"_blank\" id=\"22468132\">22468132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, &quot;Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,&quot; <i>Can J Diabetes</i>, 2013, 35(Suppl 1):1-212.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capoten (captopril) [prescribing information]. Spring Valley, NY: Par Pharmaceutical Companies Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Captopril [prescribing information]. Eatontown, NJ: West-ward Pharmaceutical Corp; June 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3063729\"></a>Castro del Castillo A, Rodriguez M, Gonzalez E, Rodriguez F, Estruch J. Dose-response effect of sublingual captopril in hypertensive crises. <i>J Clin Pharmacol</i>. 1988;28(7):667-670.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/3063729/pubmed\" target=\"_blank\" id=\"3063729\">3063729</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2179605\"></a>Ceyhan B, Karaaslan Y, Caymaz O, et al. Comparison of sublingual captopril and sublingual nifedipine in hypertensive emergencies. <i>Japan J Pharmacol</i>. 1990;52(2):189-193.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/2179605 /pubmed\" target=\"_blank\" id=\"2179605 \">2179605 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chase MP, Fiarman GS, Scholz FJ, et al, &ldquo;Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,&rdquo; <i>J Clin Gastroenterol</i>, 2000, 31(3):254-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/11034011/pubmed\" target=\"_blank\" id=\"11034011\">11034011</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8709086\"></a>Collins DA, Patel S, Eastwood JB, Bourke BE. Favourable outcome of scleroderma renal crisis. <i>J R Soc Med</i>. 1996;89(1):49P-50P.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/8709086/pubmed\" target=\"_blank\" id=\"8709086\">8709086</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo; <i>Hypertension</i>, 2000, 36(3):461-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/10988282/pubmed\" target=\"_blank\" id=\"10988282\">10988282</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper WO, Hernandez-Diaz S, Arbogast PG, et al, &ldquo;Major Congenital Malformations After First-Trimester Exposure to ACE Inhibitors,&rdquo; <i>N Engl J Med</i>, 2006, 354(23):2443-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/16760444/pubmed\" target=\"_blank\" id=\"16760444\">16760444</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9322826\"></a>Damasceno A, Ferreira B, Patel S, Sevene E, Pol&oacute;nia J. Efficacy of captopril and nifedipine in black and white patients with hypertensive crisis. <i>J Hum Hypertens</i>. 1997;11(8):471-476.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/9322826/pubmed\" target=\"_blank\" id=\"9322826\">9322826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doane J and Stults B, &ldquo;Visual Hallucinations Related to Angiotensin-Converting Enzyme Inhibitor Use: Case Reports and Review,&rdquo; <i>J Clin Hypertens (Greenwich)</i>, 2013, 15(4):230-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/23551721/pubmed\" target=\"_blank\" id=\"23551721\">23551721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duchin KL, Pierides AM, Heald A, Singhvi SM, Rommel AJ. Elimination kinetics of captopril in patients with renal failure. <i>Kid Internat</i>. 1984;25(6):942-947.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/6381858/pubmed\" target=\"_blank\" id=\"6381858\">6381858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DN. Captopril kinetics. <i>Clin Pharmacol Ther</i>. 1982;31(4):452-458.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/7037265/pubmed\" target=\"_blank\" id=\"7037265\">7037265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):2215-2245. doi: 10.1161/CIR.0000000000000105.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/25085962/pubmed\" target=\"_blank\" id=\"25085962\">25085962</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fox KM and EURopean Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators, &ldquo;Efficacy of Perindopril in Reduction of Cardiovascular Events Among Patients With Stable Coronary Artery Disease: Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial (The EUROPA Study),&rdquo; <i>Lancet</i>, 2003, 362(9386):782-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/13678872/pubmed\" target=\"_blank\" id=\"13678872\">13678872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gersh BJ, Maron BJ, Bonow RO, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2011;124(24):e783-e831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/22068434/pubmed\" target=\"_blank\" id=\"22068434\">22068434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giudicelli JF, Chaignon M, Richer C, Giroux B, Guedon J. Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients. <i>Br J Clin Pharmac</i>. 1984;18(5):749-758.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/6095887/pubmed\" target=\"_blank\" id=\"6095887\">6095887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/24243703/pubmed\" target=\"_blank\" id=\"24243703\">24243703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grossman E, Morag B, Nussinovitch N, et al, &ldquo;Clinical Use of Captopril in Takayasu's Disease,&rdquo; <i>Arch Intern Med</i>, 1984, 144(1):95-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/6140907/pubmed\" target=\"_blank\" id=\"6140907\">6140907</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(23):2610-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/22064600/pubmed\" target=\"_blank\" id=\"22064600\">22064600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurault de Ligny BH, Ryckelynck JP, Mintz P , Levy G, Muller G. Captopril therapy in preeclampsia. <i>Nephron</i>. 1987;46(3):329-330.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/3306419/pubmed\" target=\"_blank\" id=\"3306419\">3306419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) [published online December 18, 2013]. <i>JAMA</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23161035\"></a>Karakilic E, Buyukcam F, Kocalar G, Gedik S, Atalar E. Same effect of sublingual and oral captopril in hypertensive crisis. <i>Eur Rev Med Pharmacol Sci</i>. 2012;16(12):1642-1645.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/23161035/pubmed\" target=\"_blank\" id=\"23161035\">23161035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, &quot;KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease,&quot;<i>Kidney Inter, Suppl</i>, 2013, 3:1-150.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kubo SH, Cody RJ. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. <i>Clin Pharmacokin</i>. 1985;10(5):377-391.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/2994938/pubmed\" target=\"_blank\" id=\"2994938\">2994938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy M, Koren G, Klein J, et al, &ldquo;Captopril Pharmacokinetics, Blood Pressure Response and Plasma Renin Activity in Normotensive Children With Renal Scarring,&rdquo; <i>Dev Pharmacol Ther</i>, 1991, 16(4):185-93.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis EJ, Hunsicker LG, Bain RP, et al, &quot;The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy. The Collaborative Study Group,&quot; [published correction appears in <i>N Engl J Med</i>. 1993;330(2):152.] <i>N Engl J Med</i>. 1993;329(20):1456-1462.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/8413456/pubmed\" target=\"_blank\" id=\"8413456\">8413456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo; <i>J Card Fail</i>, 2010, 16(6):e1-194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/20610207/pubmed\" target=\"_blank\" id=\"20610207\">20610207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mastrobattista JM, &ldquo;Angiotensin Converting Enzyme Inhibitors in Pregnancy,&rdquo; <i>Semin Perinatol</i>, 1997, 21(2):124-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/9201818/pubmed\" target=\"_blank\" id=\"9201818\">9201818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller DR, Oliveria SA, Berlowitz DR, et al, &ldquo;Angioedema Incidence in US Veterans Initiating Angiotensin-Converting Enzyme Inhibitors,&rdquo; <i>Hypertension</i>, 2008, 51(6):1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/18413488/pubmed\" target=\"_blank\" id=\"18413488\">18413488</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mulla H, Tofeig M, Bu'Lock F, et al. Variations in Captopril Formulations Used to Treat Children With Heart Failure: A Survey in the United Kingdom. <i>Arch Dis Child</i>. 2007;92(5):409-411.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/17363396/pubmed\" target=\"_blank\" id=\"17363396\">17363396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo; <i>Pediatrics</i>, 2004, 114(2 Suppl):555-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/15286277/pubmed\" target=\"_blank\" id=\"15286277\">15286277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Onoyama K, Hirakata H, Iseki K, et al. Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure. <i>Hypertension</i>. 1981;3(4):456-459.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/7030952/pubmed\" target=\"_blank\" id=\"7030952\">7030952</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Packer M, Poole-Wilson PA, Armstrong PW, et al, &ldquo;Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure,&rdquo; <i>Circulation</i>, 1999, 100(23):2312-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/10587334/pubmed\" target=\"_blank\" id=\"10587334\">10587334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pereira CM, Tam YK, Collins-Nakai RL, &ldquo;The Pharmacokinetics of Captopril in Infants With Congestive Heart Failure,&rdquo; <i>Ther Drug Monit</i>, 1991, 13(3):209-14.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pfeffer MA, Greaves SC, Arnold JM, et al, &ldquo;Early Versus Delayed Angiotensin-Converting Enzyme Inhibition Therapy in Acute Myocardial Infarction. The Healing and Early Afterload Reducing Therapy Trial,&rdquo; <i>Circulation</i>, 1997, 95(12):2643-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/9193433/pubmed\" target=\"_blank\" id=\"9193433\">9193433</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pfeffer MA, McMurray JJ, Velazquez EJ, et al, &ldquo;Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,&rdquo; <i>N Engl J Med</i>, 2003, 349(20):1893-906.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/14610160/pubmed\" target=\"_blank\" id=\"14610160\">14610160</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quan A , &ldquo;Fetopathy Associated With Exposure to Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists,&rdquo; <i>Early Hum Dev</i>, 2006, 82(1):23-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/16427219/pubmed\" target=\"_blank\" id=\"16427219\">16427219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al; European Society of Gynecology (ESG); Association for European Paediatric Cardiology (AEPC); German Society for Gender Medicine (DGesGM); ESC Committee for Practice Guidelines. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).<i> Eur Heart J</i>. 2011;32(24):3147-3197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/21873418 /pubmed\" target=\"_blank\" id=\"21873418 \">21873418 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498. doi: 10.1016/j.jash.2015.03.002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/25840695/pubmed\" target=\"_blank\" id=\"25840695\">25840695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seely EW, Ecker J. Chronic hypertension in pregnancy. <i>Circulation</i>. 2014;129(11):1254-1261.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/24637432 /pubmed\" target=\"_blank\" id=\"24637432 \">24637432 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo; <i>Circulation</i>, 2011, 124(22):2458-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/22052934/pubmed\" target=\"_blank\" id=\"22052934\">22052934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smoger SH and Sayed MA, &ldquo;Simultaneous Mucosal and Small Bowel Angioedema Due to Captopril,&rdquo; <i>South Med J</i>, 1998, 91(11):1060-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/9824192/pubmed\" target=\"_blank\" id=\"9824192\">9824192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tosi S, Marchesoni A, Messina K, et al. Treatment of Raynaud's phenomenon with captopril. <i>Drugs Exp Clin Res</i>. 1987;13(1):37-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/3297593/pubmed\" target=\"_blank\" id=\"3297593\">3297593</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Tschollar.1985\"></a>Tschollar W, Belz GG. Sublingual captopril in hypertensive crisis. <i>Lancet</i>. 1985;2(8445):34-35.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Veterans Administration Cooperative Study Group on Antihypertensive Agents, &quot;Low-Dose Captopril for the Treatment of Mild to Moderate Hypertension. I. Results of a 14-Week Trial,&quot; <i>Arch Intern Med</i>, 1984, 144(10):1947-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/6237623/pubmed\" target=\"_blank\" id=\"6237623\">6237623</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/24341872/pubmed\" target=\"_blank\" id=\"24341872\">24341872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20117105\"></a>Wu VC, Kuo CC, Chang HW, et al. Diagnosis of primary aldosteronism: comparison of post-captopril active renin concentration and plasma renin activity. <i>Clin Chim Acta</i>. 2010;411(9-10):657-663.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/20117105/pubmed\" target=\"_blank\" id=\"20117105\">20117105</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America [published online May 20, 2016]. <i>Circulation</i>. doi: 10.1161/CIR.0000000000000435.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/27208050/pubmed\" target=\"_blank\" id=\"27208050\">27208050</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yusuf S, Sleight P, Pogue J, et al, &ldquo;Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators,&rdquo; <i>N Engl J Med</i>, 2000, 342(3):145-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/captopril-drug-information/abstract-text/10639539/pubmed\" target=\"_blank\" id=\"10639539\">10639539</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9196 Version 221.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708658\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F145364\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F145413\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F145368\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F145389\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F145369\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F145370\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15682459\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F145337\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F145321\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F23610421\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F802614\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F145340\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25722081\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F145421\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F145328\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F145344\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F145325\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F145407\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F145330\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F145358\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F145333\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F145347\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6195942\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F145335\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F50148483\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F145324\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F145343\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F145346\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F145350\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9196|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=captopril-patient-drug-information\" class=\"drug drug_patient\">Captopril: Patient drug information</a></li><li><a href=\"topic.htm?path=captopril-pediatric-drug-information\" class=\"drug drug_pediatric\">Captopril: Pediatric drug information</a></li></ul></div></div>","javascript":null}